BioCentury published the article "Competing for growth"
2017-05-15Research
Part of an article originally posted by Biocentury about the potential new therapies for achondroplasia and how the competition between the pharmaceutical companies is being beneficial for the final product.

Phase 3 trial for achondroplasia - BioMarin Study 111-301
2017-05-12Research
Highlights of the Phase 3 clinical trial design for BMN-111, developed by BioMarin. Learn more about how it's going to be processed here.

The TransCon CNP, a prodrug for achondroplasia
2017-04-09Research
Ascendis Pharma is developing a drug for achondroplasia, using new technology that combines the benefits of a pro-drug and sustained-release technologies. Learn more about TransCon CNP here.
A challenging report on Vosoritide
2016-11-23Research
Although BioMarin's results for Vosoritide have been mostly positive, there are some concerns regarding the less positive results.

BioMarin presents report on phase 2 study of Vosoritide
2016-10-20Research
BioMarin has issued a new press release with data on the phase 2 clinical trial for Vosoritide, during the ASHG 2016 meeting. Read all about it here.
State of the art in achondroplasia
2016-06-30Research
This is a summary of the current state of drug development in achondroplasia.